Tempest Therapeutics Registers 2.4M Shares for Resale, Could Raise $4.2M from Warrant Exercises

summarizeSummary

Tempest Therapeutics filed a prospectus for the resale of up to 2.4 million shares underlying warrants, which could provide the company with up to $4.23 million in cash from warrant exercises, crucial for its liquidity.

check_boxKey Events · Financing and Capital Events · TPST

• Resale Registration

  Registers up to 2,426,897 shares of common stock for resale by selling stockholders, including Sabby Volatility Warrant Master Fund, Ltd.

• Potential Capital Infusion

  The company could receive approximately $4.23 million if all underlying warrants are exercised for cash, which would more than double its reported cash balance of $1.8 million.

• Dilution Impact

  The full exercise of these warrants would increase the outstanding share count by about 15%, from 15.98 million to 18.41 million shares.

• Warrant Pricing Above Market

  The exercise prices for the New Warrants ($1.73 per share) and Placement Agent Warrants ($2.1625 per share) are significantly above the current stock price of $0.98.

auto_awesomeAnalysis · TPST · Life Sciences

This filing registers shares underlying warrants for resale by selling stockholders. While the company won't receive proceeds from the resale, it stands to gain up to $4.23 million if all warrants are exercised for cash. This potential capital infusion is critical for Tempest Therapeutics, which recently reported a 'going concern' warning and a low cash balance of $1.8 million. The warrant exercise prices ($1.73 and $2.16) are notably above the current stock price of $0.98, indicating a premium paid by investors for future shares. However, the exercise of these warrants would result in significant dilution for existing shareholders, adding approximately 15% to the outstanding share count.